PRESENTATION

Q1 2026 — Presentation

Q1 2026PDF · 16 pages254 KB
Elevance Health
1Q 2026 Supplemental
Earnings Presentation
April 22, 2026

-- 1 of 16 --

2
Key Highlights
First quarter adjusted EPS exceeded expectations, driven by business strength and favorable claims experience
• 	Adjusted diluted EPS1 of $12.58 reflects underlying business strength and improving claims experience, along with
ACA seasonality and approximately $1 per share of non-recurring net investment income
• 	Operating revenue of $49.5B increased 1.5% due to higher premium yields and disciplined pricing actions
• 	Benefit expense ratio of 86.8% driven by modestly favorable claims experience, our cost management initiatives,
and ACA seasonality
• 	Returned $1.5B to shareholders through share repurchases and dividends, reflecting robust cash generation
• 	Accrued $935M representing our current best estimate of the identified potential exposure to the CMS Notice2
1Q 2026 Results
1
Raised 2026 adjusted diluted EPS 1 guidance to at least $26.75, supported by underlying business strength, improving
claims experience, and increased visibility
• 	Reflects strength of our first quarter operating results and higher net investment income
• 	Principal operating elements of our 2026 guidance framework remain appropriate
• 	Reaffirm operating cash flow of at least $5.5B, inclusive of potential cash payments to resolve the CMS matter
Expect to return to at least 12% adjusted diluted EPS growth in 2027, off our revised 2026 earnings baseline of $25.75 3
2026 Outlook
2
Realigned leadership structure to strengthen execution, improve accountability, and enhance coordination across
clinical, operational, and financial performance
Scaling AI to improve member engagement, support cost trend improvement, and drive operating leverage
Growing demand for Carelon’s capabilities to manage risk, improve outcomes, and reduce costs
Executing across the portfolio to improve performance in Medicaid and Medicare Advantage, maintain pricing
discipline in Commercial, strengthen Carelon’s growth, and deliver consistent results over time
Strategic Focus
Areas3
1. 	See “GAAP Reconciliation” on slides 14 and 15 herein.
2. 	Represents the Company's current best estimate of the identified potential exposure for certain historical Medicare Advantage risk adjustment data related to the CMS Notice to the Company dated February 27, 2026.
3. 	2026 earnings baseline excludes the ~$1 per share of non-recurring net investment income recognized in 1Q 2026.

-- 2 of 16 --

33
Raised 2026 Adjusted Diluted EPS Guidance To At Least $26.75
2026 Adjusted Diluted EPS Guidance 1 2026 Seasonality
>$25.50 ~$0.15
~($0.15)
~$0.25 	>$25.75
~$1 	>$26.75
Initial 2026
Adjusted EPS
Guidance
1Q
Seasonality
2H
Seasonality
1Q
Outperformance
2026 Earnings
Baseline
Non-Recurring
Net Investment
Income Gains
Current 2026
Adjusted EPS
Guidance
1Q,
47%
2Q,
~23%
2H,
~30%
2026 Adjusted EPS
Guidance
>$26.75
1H,
~70%
Supported by underlying business strength, improving claims experience, and increased visibility
1. 	Adjusted EPS refers to Adjusted Diluted Earnings Per Share. See “GAAP Reconciliation” on slides 14 and 15 herein.
2. 	Initial 2026 Adjusted EPS Guidance as of January 28, 2026
3. 	Current 2026 Adjusted EPS Guidance as of April 22, 2026
2 	3

-- 3 of 16 --

44
Actions Driving Improvement in Healthcare Cost Trends
• 	Value-based oncology model reduces chemotherapy-related admissions by 50% in
our Commercial risk-based business
• 	HealthOS reduces documentation requests by >60% and accelerates prior
authorization turnaround times
• 	CarelonRx improves access and adherence, delivering up to $100 PMPM savings
• 	Value-based specialty drug management lowers total cost of care
• 	Enhanced claim accuracy reduces unnecessary specialty drug spend
• 	Medicaid interventions in ABA therapy and substance use disorder improve care
coordination and outcomes
• 	Mosaic Health reduces avoidable utilization via proactive, advanced primary care
• 	AI-enabled digital assistant guides members to more effective, affordable care
• 	Intelligent automation improves claims accuracy, reduces rework, and lowers
administrative costs
Outpatient Costs: Reducing avoidable utilization through proactive interventions
Hospital Costs: Reducing utilization and high-cost admissions
Operational Costs: Improving efficiency and lowering administrative expense
Prescription Drugs: Improving cost management and reducing unnecessary spend
Healthcare
Insurance
Premium 1
Insurer Earnings
1Represents allocation of a commercial premium dollar across medical care, as well as related services and essential services. Source: AHIP.
1
2
3
4
Targeted actions across key cost drivers are improving trends and supporting stronger performance

-- 4 of 16 --

55
Key Highlights
• 	First quarter adjusted diluted EPS
exceeded our outlook, driven by
underlying business strength and
improving claims experience
• 	Adjusted EPS of $12.58 reflects core
performance, ACA seasonality, and
approximately $1.00 of non-recurring
investment income
• 	Operating revenue growth was driven
by higher premium yields and
CarelonRx product revenue, partially
offset by anticipated declines in our
Medicare Advantage, Medicaid, and
Employer Group risk membership
• 	Benefit expense ratio of 86.8% reflects
expected elevated cost trends in
Medicaid, partly offset by improving
claims experience in Medicare
• 	Operating cash flow of $4.3B reflects
strong business performance and
favorable working capital dynamics
1Q 2026 Results
Change	1Q 2025	1Q 2026	Elevance Health
1.5%	$48.8B	$49.5B	Operating Revenue1
40 bps	86.4%	86.8%	Benefit Expense Ratio
(20) bps	10.7%	10.5%	Adjusted Operating Expense Ratio 2
(1.6%)	$3.3B	$3.2B	Adjusted Operating Gain1,2
(20) bps	6.7%	6.5%	Adjusted Operating Margin 1,2
29.7%	$590M	$765M	Net Investment Income
5.1%	$11.97	$12.58	Adjusted Diluted EPS 2
$3.3B	$1.0B	$4.3B	Operating Cash Flow
1. 	See “Non-GAAP Measures and Basis of Presentation” on slide 13 herein.
2. 	See “GAAP Reconciliation” on slides 14 and 15 herein.

-- 5 of 16 --

66
Key Highlights
• 	Performance reflects improving claims
experience relative to expectations,
supported by disciplined pricing and
targeted cost management actions
• 	Operating revenue grew 2.6% year over
year, driven by higher premium yields,
partially offset by deliberate actions to
reposition our Medicare Advantage
and Employer Group risk businesses,
and Medicaid membership attrition
• 	Operating margin of 5.1% declined by
30 bps, due to anticipated higher
medical costs, primarily in Medicaid
• 	Membership of 45.4M reflects the
results of a strong National Accounts
selling season, offset by expected
reductions in our Medicaid, Medicare
Advantage, and Employer Group risk
membership
Change	1Q 2025	1Q 2026	Health Benefits
2.6%	$41.4B	$42.5B	Operating Revenue 1
(2.7%)	$2.2B	$2.2B	Operating Gain1,2
(30) bps	5.4%	5.1%	Operating Margin 1,2
(0.9%)	45.8M	45.4M	Membership
1. 	See “Non-GAAP Measures and Basis of Presentation” on slide 13 herein.
2. 	See “Reportable Segment Highlight & Health Benefits Revenue Details” on slide 16 herein.
Health Benefits
1Q 2026 Results

-- 6 of 16 --

77
Key Highlights
• 	Performance reflects continued
investment and scaling of risk-based
capabilities, with improving contribution
from specialty pharmacy and behavioral
health, supporting long-term growth
• 	CarelonRx operating revenue benefited
from higher revenue per adjusted script,
partly offset by lower script volumes due
to health plan membership attrition;
operating margin reflects lower
Commercial risk-based membership,
partly offset by improved profitability in
specialty pharmacy
• 	Carelon Services operating revenue
supported by continued scaling of its risk-
based solutions; operating margin
impacted by lower health plan
membership and continued investment in
the expansion of risk-based solutions
1Q 2026 Results
Change	1Q 2025	1Q 2026	Carelon
7.9%	$16.7B	$18.0B	Operating Revenue 1
(3.8%)	$1.1B	$1.1B	Operating Gain1,2
(70) bps	6.6%	5.9%	Operating Margin 1,2
(4.3%)	83.9M	80.3M	Adjusted Scripts
(6.6%)	99.5M	92.9M	Consumers Served
1. 	See “Non-GAAP Measures and Basis of Presentation” on slide 13 herein.
2. 	See “Reportable Segment Highlight & Health Benefits Revenue Details” on slide 16 herein.
Health Services

-- 7 of 16 --

88
Elevance Health is a Lifetime, Trusted Health Partner
Lowering the cost of healthcare
We anticipate health trends early, give
caregivers the tools they need, and
make care easier to afford.
Making healthcare simple
We make accessing and using healthcare easy,
cutting red tape and simplifying systems and
processes so providers can provide care, and
members can live their healthiest lives.
To deliver on our mission of improving lives and communities and simplifying healthcare
WHAT
HOW
WHY
A lifetime, trusted health partner
committed to making healthcare better…
better costs, better experience, better
outcomes – for your whole health.

-- 8 of 16 --

99
Flywheel Supports Our Long-Term Growth Algorithm
Health Benefits
Optimize
the Core
Invest in
Growth
Accelerate
Performance
Targeting at least 12% average annual growth in
Adjusted Diluted Earnings Per Share
Over 45M medical members balanced
across commercial, Medicaid, Medicare,
and the Federal Employee Program,
leveraging the assets and capabilities
of Carelon to accelerate growth
As an integrated portfolio of whole
health solutions serving approximately
93M consumers, Carelon connects care
across physical, behavioral, social,
home health, and pharmacy needs to
bend the cost curve, enhance consumer
experiences, and deliver whole health,
affordably
Health Services

-- 9 of 16 --

10	10
Adjusted Operating Gain – High Single Digit to Low Double Digit CAGR1
Long-Term Growth Algorithm
Revenue Growth
High Single Digit CAGR1
Adjusted Operating Margin
Expanding to 5.0% – 6.0%
Capital Deployment
Approximately 4% Contribution to
Adjusted Diluted EPS CAGR 1
Health Benefits
Mid to High Single Digit CAGR
Driven by targeted membership growth, strategic
geographic and product expansion, and growth in
specialized populations
Carelon Services
High Teens to Low Twenties CAGR
Driven by risk-based revenue growth and M&A
CarelonRx
Low Double Digit CAGR
Driven by new client relationships and scaling of
specialty pharmacy capabilities
Strengthen operational
discipline to accelerate margin
normalization
Advance value-based care
models to improve outcomes
and reduce costs
Integrate technology to simplify
the experience for members and
care providers
Share Repurchases
Organic Reinvestment
Programmatic M&A targeting
integrated solutions that
strengthen health plan
competitiveness
+ 	+
1. 	CAGR = Compound Annual Growth Rate Target.
Targeting at least 12% average annual growth in Adjusted Diluted EPS

-- 10 of 16 --

11	11
Committed to Strong Growth Over the Long-Term
M&A/ Organic
Reinvestment
50%
Share
Repurchase
30%
Dividends
20%
3.8%
5.0% – 6.0%
2025 	Target
$198B
High Single
Digit CAGR1
2025 	Target
Elevance Health
4.8%
Mid Single
Digit
2025 	Target
$72B
Mid Teens
CAGR1
2025 	Target
Carelon 2
2.5%
Mid Single
Digit
2025 	Target
$167B
Mid to High
Single Digit
CAGR1
2025 	Target
Health Benefits
Capital
Allocation
Targeting at least 12% average annual
growth in Adjusted Diluted EPS
Adjusted 3
Operating
Margin
Revenue
(in billions)
1. 	CAGR = Compound Annual Growth Rate Target.
2. 	The CAGR target for revenue and the operating margin target for Carelon includes: (i) a low double digit revenue CAGR and mid single digit percentage operating margin for
CarelonRx, and (ii) a high teens to low twenties revenue CAGR and mid to high single digit percentage operating margin for Carelon Services.
3. 	See “GAAP Reconciliation” on slides 14 and 15 herein.

-- 11 of 16 --

12
Forward-Looking Statements
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views
about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,”
“project,” “forecast,” “plan,” “potential,” “predict” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to:
financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and
services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond
our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place
undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other
disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect
our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof.
These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient
premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing
federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services,
or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or
regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our information
systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and
market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry
and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with
the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores
and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation,
government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy
and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement
between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity or sentiment related to the health benefits industry in general or us in particular; risks associated
with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and
other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares
of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our
substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a
downgrade in our financial strength ratings; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain
employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business
combinations.

-- 12 of 16 --

13
Non-GAAP Measures and Basis of Presentation
This document references non-GAAP measures, including “Adjusted Diluted EPS,” “Adjusted Operating Expense Ratio,” “Adjusted Operating Gain,” “Adjusted Operating Margin,”
“Adjusted Shareholders’ Net Income,” and “Adjusted Operating Expense”. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial
results among periods and are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most
directly comparable measures calculated in accordance with GAAP are available on slides 14-15 of this document.
In addition to these non-GAAP measures, references are made to the measures “Operating Revenue,” “Operating Gain/Loss,” and “Operating Margin”. Operating revenue and
operating gain/loss are the key measures used by management to evaluate performance in each of its reportable segments, allocate resources, set incentive compensation
targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of products sold and operating
expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets and gains/losses on
extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment
management. Each of these measures is provided to further aid investors in understanding and analyzing Elevance Health’s operating and financial results. A reconciliation of
reportable segments operating gain to income before income tax expense is available on slide 14 of this document. Prior amounts may be grouped differently to conform to the
current presentation.

-- 13 of 16 --

14	14
GAAP Reconciliation — Shareholders’ Net Income and Shareholders’
Earnings Per Diluted Share Twelve Months Ended Dec 31	Three Months Ended Mar 31
Change	2024	2025	Change	2025	2026	(In millions, except per share data)
(5.3%)	$5,980	$5,662	(19.2%)	$2,183	$1,764	Shareholders' net income
Add / (Subtract):
—	—	—	935	Accrual related to CMS notice1,2
268	(38)	—	129	Business optimization program charges1
580	628	155	112	Amortization of other intangible assets
445	653	464	78	Net losses on financial instruments
224	236	80	47	Transaction and integration related costs 1
692	24	5	7	Litigation and settlement expenses 1
281	41	—	—	Business dispositions and related items 3
(201)	—	—	—	Gain on sale of business
(575)	(402)	(168)	(300)	Tax impact of non-GAAP adjustments
1,714	1,142	536	1,008	Net adjustment items
(11.6%)	$7,694	$6,804	1.9%	$2,719	$2,772	Adjusted shareholders' net income
(1.8%)	$25.68	$25.21	(16.8%)	$9.61	$8.00	Shareholders’ earnings per diluted share
Add / (Subtract):
—	—	—	4.24	Accrual related to CMS notice1,2
1.15	(0.17)	—	0.59	Business optimization program charges1
2.49	2.80	0.68	0.51	Amortization of other intangible assets
1.91	2.91	2.04	0.35	Net losses on financial instruments
0.96	1.05	0.35	0.21	Transaction and integration related costs 1
2.97	0.11	0.02	0.03	Litigation and settlement expenses 1
1.21	0.18	—	—	Business dispositions and related items 3
(0.86)	—	—	—	Gain on sale of business
(2..47)	(1.79)	(0.74)	(1.36)	Tax impact of non-GAAP adjustments
7.36	5.08	2.36	4.58	Net adjustment items
(8.3%)	$33.04	$30.29	5.1%	$11.97	$12.58	Adjusted shareholders’ earnings per diluted share 4
Twelve Months Ended Dec 31	Three Months Ended Mar 31
Change	2024	2025	Change	2025	2026	(In millions)
(15.1%)	$7,904	$6,710	(17.6%)	$2,797	$2,304	Income before income tax expense
(2,051)	(2,194)	(590)	(765)	Net investment income
(201)	—	—	—	Gain on sale of business
445	653	464	78	Net losses on financial instruments
580	628	155	112	Amortization of other intangible assets
1,185	1,402	344	357	Interest expense
(8.4%)	$7,862	$7,199	(34.2%)	$3,170	$2,086	Reportable segments operating gain
1. Adjustment item resides in the Corporate & Other reportable segment
2. Adjustment item represents the Company's current best estimate of the identified potential exposure for certain historical Medicare Advantage risk adjustment data related to the CMS notice to the Company dated February 27, 2026.
3. Adjustment item resides in the Health Benefits, CarelonRx, Carelon Services, and Corporate & Other reportable segments
4. Totals may not foot due to rounding.

-- 14 of 16 --

15	15
GAAP Reconciliation — Operating Gain, Operating Expense Ratio, and
2026 Outlook
(In millions)
4.8%	$20,025	$20,984	19.4%	$5,300	$6,330	Operating expense
Add / (Subtract):
—	—	—	(935)	Accrual related to CMS notice1,2
(268)	38	—	(129)	Business optimization program charges1
(224)	(236)	(80)	(47)	Transaction and integration related costs 1
(692)	(24)	(5)	(7)	Litigation and settlement expenses 1
(281)	(41)	—	—	Business dispositions and related items 3
(1,465)	(263)	(85)	(1,118)	Net adjustment items
11.6%	$18,560	$20,721	(0.1%)	$5,215	$5,212	Adjusted operating expense
12.8%	$175,204	$197,584	1.5%	$48,765	$49,494	Operating revenue
(80) bp	11.4%	10.6%	190 bp	10.9%	12.8%	Operating expense ratio
(10) bp	10.6%	10.5%	(20) bp	10.7%	10.5%	Adjusted operating expense ratio
Twelve Months Ended Dec 31	Three Months Ended Mar 31
Change	2024	2025	Change	2025	2026	(In millions)
(8.4%)	$7,862	$7,199	(34.2%)	$3,170	$2,086	Reportable segments operating gain
Add / (Subtract):
—	—	—	935	Accrual related to CMS notice1,2
268	(38)	—	129	Business optimization program charges1
224	236	80	47	Transaction and integration related costs 1
692	24	5	7	Litigation and settlement expenses 1
281	41	—	—	Business dispositions and related items 3
1,465	263	85	1,118	Net adjustment Items
(20.0%)	$9,327	$7,462	(1.6%)	$3,255	$3,204	Reportable segments adjusted operating gain
Full Year 2026 Outlook
At least $19.85	Shareholders’ earnings per diluted share
Add / (Subtract):
$4.24	Accrual related to CMS notice1,2
$2.00	Amortization and other intangible assets 4
$1.15	Net losses on financial instruments4
$0.90	Transaction and integration related costs 1,4
$0.59	Business optimization program charges1
$0.10	Litigation and settlement expenses 1,4
Approximately ($2.08)	Tax impact of non-GAAP adjustments 4
$6.90	Net adjustment items
At least $26.75	Adjusted shareholders’ earnings per diluted share	
1. Adjustment item resides in the Corporate & Other reportable segment.
2. Adjustment item represents the Company's current best estimate of the identified potential exposure for certain historical Medicare Advantage risk adjustment data related to the CMS notice to the Company dated February 27, 2026.
3. Adjustment item resides in the Health Benefits, CarelonRx, Carelon Services, and Corporate & Other reportable segments
4. Adjustment item represents the midpoint of a projected range and serves as the estimated full year adjustment amount.
12.8%	$175,204	$197,584	1.5%	$48,765	$49,494	Operating revenue
(90) bp	4.5%	3.6%	(230) bp	6.5%	4.2%	Operating margin
(150) bp	5.3%	3.8%	(20) bp	6.7%	6.5%	Adjusted operating margin

-- 15 of 16 --

16	16
Reportable Segment & Health Benefits Revenue Details
Three Months Ended Mar 31
Change	2025	2026	(In millions, Unaudited)
Operating Revenue
2.6%	$41,431	$42,490	Health Benefits
4.8%	10,116	10,600	CarelonRx
12.7%	6,536	7,365	Carelon Services
(97.6%)	165	4	Corporate & Other
NM 6	(9,483)	(10,965)	Eliminations
1.5%	$48,765	$49,494	Total Operating Revenue1
Operating Gain (Loss)
(2.7%)	$2,217	$2,157	Health Benefits
(3.3%)	602	582	CarelonRx
(4.3%)	491	470	Carelon Services
NM 6	(140)	(1,123)	Corporate & Other 2,3
(34.2%)	$3,170	$2,086	Total Operating Gain1,4
Operating Margin
(30) bp	5.4%	5.1%	Health Benefits
(50) bp	6.0%	5.5%	CarelonRx
(110) bp	7.5%	6.4%	Carelon Services
(230) bp	6.5%	4.2%	Total Operating Margin1
1. 	See “Basis of Presentation” on slide 13 herein.
2. 	Operating Gain for the three months ended March 31, 2026 included $935 million for the Company's current best estimate of the identified potential exposure for certain historical Medicare Advantage risk adjustment data related to the CMS notice to the Company dated February 27, 2026, $129 million of business
optimization program charges, $47 million of transaction and integration related costs, and $7 million of litigation and settlement expenses, which reside in the Corporate & Other reportable segment.
3. 	Operating Gain for the three months ended March 31, 2025 included $80 million of transaction and integration related costs and $5 million of litigation and settlement expenses, which reside in the Corporate & Other reportable segment.
4. 	Operating Gain for the three months ended March 31, 2026, and March 31, 2025, included items excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on pages 14 and 15 herein.
5. 	The Individual business, including ACA products, is reported as part of Commercial Operating Revenue.
6. 	"NM" = calculation not meaningful.
Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal Employee Program
businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the quantitative thresholds for an operating division as well as corporate expenses not
allocated to our other reportable segments).
Three Months Ended Mar 31
Change	2025	2026	(In millions, Unaudited)
Health Benefits Operating Revenue
7.2%	$12,352	$13,238	Commercial
7.6%	2,361	2,540	Individual 5
(3.6%)	11,406	10,991	Medicare
1.7%	14,043	14,280	Medicaid
9.7%	3,630	3,981	Federal Employee Program
2.6%	$41,431	$42,490	Total Health Benefits Operating Revenue1

-- 16 of 16 --